Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia

Abstract

Key Points Dinaciclib enhances NK-cell activity against leukemia cells in preclinical AML models. Enhanced NK-cell activation by dinaciclib-treated AML is associated with downregulation of inhibitory NK ligand HLA-E on leukemia cells.